Although no EGFR-targeted HCC treatments are presently available for clinical use [14,15,16,17], EGFR TKIs showed their synergistic benefit with sorafenib therapy through in vitro and in vivo studies [18,19], and the possible role of EGFR TKIs for the improvement of the efficacy of sorafenib in HCC is being assessed in clinical trials [19]. This evidence concerns the gene EGFR and hepatocellular carcinoma.